Test story II

By: NewsUSA

(NewsUSA) - For more details, including important safety information, on VenaSeal, visit: https://www.medtronic.com/breakfree.

Sources

  1. Gloviczki P, Comerota AJ, Dalsing MC, et al. The care of patients with varicose veins and associated chronic venous diseases: Clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. J Vasc Surg. 2011;53(5 Suppl):2S–48S. doi: 10.1016/j.jvs.2011.01.079.
  2. Mayo Clinic: Varicose Veinshttps://www.mayoclinic.org/diseases-conditions/varicose-veins/symptoms-causes/syc-20350643
  3. National Heart Lung and Blood Institute: Varicose Veins https://www.nhlbi.nih.gov/health/varicose-veins
  4. Morrison N, Gibson K, McEnroe S, et al. Randomized trial comparing cyanoacrylate embolization and radiofrequency ablation for incompetent great saphenous veins (VeClose). J Vasc Surg. 2015;61(4):985–994. doi: 10.1016/j.jvs.2014.11.071.
  5. Proebstle T, Alm J, Dimitri S, et al. Three-year follow-up results of the prospective European multicenter cohort study on cyanoacrylate embolization for treatment of refluxing great saphenous veins. J Vasc Surg Venous Lymphat Disord. 2021;9(2):329–334. doi: 10.1016/j.jvsv.2020.05.019.
  6. Almeida JI, Javier JJ, Mackay EG, Bautista C, Cher DJ, Proebstle TM. Thirty-sixth-month follow-up of first-in-human use of cyanoacrylate adhesive for treatment of saphenous vein incompetence. J Vasc Surg Venous Lymphat Disord. 2017;5(5):658–666. doi: 10.1016/j.jvsv.2017.03.016.

Mar 28, 2025 09:26 am

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  211.18
+3.94 (1.90%)
AAPL  252.67
+1.03 (0.41%)
AMD  219.95
+14.58 (7.10%)
BAC  48.70
+0.56 (1.17%)
GOOG  287.72
-1.48 (-0.51%)
META  593.93
+1.01 (0.17%)
MSFT  369.77
-2.97 (-0.80%)
NVDA  178.12
+2.92 (1.67%)
ORCL  144.69
-2.40 (-1.63%)
TSLA  385.14
+2.11 (0.55%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.